Latest news with #Lucentis
Yahoo
15-05-2025
- Business
- Yahoo
Lucentis (Ranibizumab) Market Research Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2019-2024, 2024-2029F, 2034F
Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Lucentis (Ranibizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to Lucentis (Ranibizumab) market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market. Major players operating in the lucentis (ranibizumab) market are Roche Ltd, Novartis AG. North America was the largest region in the lucentis (ranibizumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lucentis (ranibizumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the lucentis (ranibizumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, growth in the historic period can be attributed to the growing prevalence of age-related macular degeneration (AMD), approval and reimbursement by regulatory authorities, demonstrated efficacy and clinical outcomes, strong brand recognition, and physician adoption of Lucentis. The emergence of biosimilars and increased cost competition also played a significant role in driving market growth during the forecast period can be attributed to the increasing incidence of diabetic retinopathy (DR) and diabetic macular edema (DME), advancements in treatment protocols and combination therapies, and the aging population contributing to a rising prevalence of retinal diseases. Additionally, expanding market access in emerging markets, ongoing clinical research, and the potential for new indications will boost growth. Major trends in the forecast period include a shift toward longer-interval dosing and maintenance treatment, growing adoption of biosimilars and alternative treatments, the rise of personalized medicine approaches for retinal diseases, increased demand in emerging markets due to improving healthcare access, and the integration of digital health solutions in treatment monitoring. The rising prevalence of eye-related disorders is expected to drive the growth of the lucentis (ranibizumab) market. Eye-related disorders encompass various conditions that impair the proper functioning of the eyes, and their prevalence is increasing due to factors such as aging, genetic predisposition, lifestyle choices like smoking and poor diet, and environmental influences such as prolonged sun exposure and excessive digital screen use. Lucentis works by inhibiting vascular endothelial growth factor (VEGF), which is responsible for abnormal blood vessel growth and leakage in the retina, common causes of conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME). According to the National Eye Institute, 2.2 million Americans will be blind by 2030, indicating a growing need for treatments like Lucentis. Thus, the rising prevalence of eye-related disorders is driving the market for rise in healthcare spending is a key factor propelling the growth of the lucentis (ranibizumab) market. Healthcare spending, which includes financial resources allocated by individuals, governments, and insurers for healthcare services and products, is increasing due to factors like an aging population, advancements in medical technology, and the rising prevalence of chronic diseases. This growth in healthcare expenditure helps to ensure that treatments like Lucentis are accessible, enabling widespread use in treating retinal diseases such as AMD and DME. It also supports the reimbursement, coverage, and distribution of the drug, ultimately improving patient outcomes and reducing the long-term burden of vision loss. For instance, healthcare spending in the UK increased by 5.6% in 2023, reflecting a larger trend of rising healthcare investments that support the lucentis market.A key trend in the lucentis (ranibizumab) market is the development of biosimilars to offer more affordable alternatives to the branded product. Biosimilars are biologic medical products that are highly similar to an already approved reference biologic in terms of structure, efficacy, and safety, with no clinically meaningful differences. For example, in April 2024, Formycon AG and Bioeq AG launched FYB201, a biosimilar version of Lucentis, in Canada and Switzerland. Known as Ranopto and Ranivisio in these markets, respectively, the biosimilar provides a more cost-effective option for patients suffering from retinal diseases. Like Lucentis, FYB201 inhibits VEGF-A, a protein that causes abnormal blood vessel growth in the retina, leading to conditions like swelling and vision impairment. The approval and launch of such biosimilars contribute to market growth by expanding access to Topics Covered: 1. Executive Summary2. Lucentis (Ranibizumab) Market Characteristics3. Lucentis (Ranibizumab) Market Biologic Drug Characteristics3.1. Molecule Type3.2. Route of Administration (ROA)3.3. Mechanism of Action (MOA)3.4. Safety and Efficacy4. Lucentis (Ranibizumab) Market Trends and Strategies5. Lucentis (Ranibizumab) Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market6. Global Lucentis (Ranibizumab) Growth Analysis and Strategic Analysis Framework6.1. Global Lucentis (Ranibizumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)6.2. Analysis of End Use Industries6.3. Global Lucentis (Ranibizumab) Market Growth Rate Analysis6.4. Global Lucentis (Ranibizumab) Historic Market Size and Growth, 2019-2024, Value ($ Billion)6.5. Global Lucentis (Ranibizumab) Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)6.6. Global Lucentis (Ranibizumab) Total Addressable Market (TAM)7. Global Lucentis (Ranibizumab) Market Pricing Analysis & Forecasts8. Lucentis (Ranibizumab) Market Segmentation8.1. Global Lucentis (Ranibizumab) Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Single-use Prefilled Syringe Single-use Glass Vial 8.2. Global Lucentis (Ranibizumab) Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Age-related Macular Degeneration Diabetic Retinopathy Retinal Vein Occlusion Myopic Choroidal Neovascularization Uveitis 8.3. Global Lucentis (Ranibizumab) Market, Segmentation by End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Hospitals Clinics Ambulatory Surgical Centers Other End-Users 9. Global Lucentis (Ranibizumab) Market Epidemiology of Clinical Indications9.1. Drug Side Effects9.2. Incidence and Prevalence of Clinical Indications10. Lucentis (Ranibizumab) Market Regional and Country Analysis10.1. Global Lucentis (Ranibizumab) Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion10.2. Global Lucentis (Ranibizumab) Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Associated Press
29-04-2025
- Business
- Associated Press
Tavo Biotherapeutics Announces Appointment of Seasoned Executives to Key Posts
---- Lukas Scheibler, Ph.D. to become Chief Research and Development Officer and Graham Cooper to become Chief Financial Officer ---- Additions to senior team will drive Tavo's strategy to develop new innovative therapeutics addressing critical unmet needs in glaucoma and retinal disease IRVINE, Calif. , April 29, 2025 /PRNewswire/ -- Tavo Biotherapeutics, a leading innovator in the ophthalmology industry, today announced the appointment of Lukas Scheibler, Ph.D. as Chief Research and Development Officer, and Graham Cooper as Chief Financial Officer. Both bring proven track records of success in the biotechnology industry. 'I am thrilled to bring on Lukas and Graham to Tavo's senior team,' said Gary Berman, Chief Executive Officer. 'Lukas has had an illustrious career in ophthalmology, from introducing Lucentis in Europe for Novartis, running clinical development at Alcon, and pioneering the development of Syfovre for geographic atrophy at Apellis. He is a recognized leader in the industry, and he will play a central role in driving our clinical and pre-clinical programs in treatments for glaucoma and retinal disease.' Berman continued, 'Likewise, Graham has extensive experience in the biotech field, across multiple therapeutic indications. Throughout his career he has raised over a billion dollars in capital, having taken companies public and scaled enterprises from the early stages, hiring teams and managing growth. He is a recognized leader in the venture capital and public investor communities and brings a wealth of experience and strong relationships to Tavo. Lukas and Graham fill pivotal roles for Tavo, and they join us at a key time as we prepare to raise capital and advance our pipeline into the clinic. Attracting these accomplished executives builds on our momentum in developing breakthrough therapies that address fundamental unmet needs in ophthalmology.' Dr. Lukas Scheibler was most recently Chief Innovation Officer at Apellis. In this role, he was responsible for all research and development activities through human proof of concept. Prior to that, he was Head of Clinical Development at Alcon, where he was responsible for the planning and execution of all clinical trials. Dr. Scheibler began his career in ophthalmology in research and development at Novartis, where he played a key role in the in-licensing and approval of Lucentis in Europe. He holds a Ph.D. from the University of Lausanne, Switzerland, and completed postdoctoral training at Harvard Medical School. Graham Cooper was Chief Financial Officer for Receptos, which he joined prior to its IPO. At Receptos, he played a key role in managing through a dramatic growth phase and raising capital, culminating in its sale to Celgene for $7.8 billion. He also served as Chief Financial Officer and Chief Operating Officer of Assembly Biosciences, developing innovative anti-viral therapies for the treatment of HBV, as well as other private and public biotechnology companies. Prior to his operating roles, Mr. Cooper held positions of increasing responsibility at Deutsche Bank Securities, including Director, Health Care Investment Banking. He began his career at Deloitte & Touche and was previously a CPA. Mr. Cooper currently serves as a member of the board of Beam Therapeutics (BEAM) and chairman of the board of Kezar Life Sciences (KZR). Mr. Cooper received a BA in Economics from the University of California at Berkeley and an MBA from the Stanford Graduate School of Business. About Tavo Biotherapeutics Tavo Biotherapeutics is developing innovative new treatments to address critical unmet needs in ophthalmology. TAV-001 is being developed for the treatment of glaucoma-related neurodegeneration. In pre-clinical studies, TAV-001 has shown substantial reduction in intraocular pressure, as well as signals of neuroprotection, suggesting that it could represent the first disease-modifying pharmaceutical therapy for these patients. TAV-001 is expected to enter a Phase 1 clinical trial in glaucoma patients in 2025. TAV-002 represents a potential first-in-class treatment for retinal disease, including diabetic macular edema and diabetic retinopathy, as well as both wet and dry age-related macular degeneration. Tavo has initiated IND-enabling activities for this program. Media Contact: Graham Cooper Chief Financial Officer [email protected] View original content: SOURCE Tavo Biotherapeutics
Yahoo
02-04-2025
- Business
- Yahoo
Leqembi's EU review drags on; Sanofi gets a new development head
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving Eisai, Biogen and Sanofi, as well as updates from Opthea, Novartis, and PTC Therapeutics. The saga to get Eisai and Biogen's newer drug for Alzheimer's disease approved in Europe continues. On Tuesday, the partners disclosed that the European Commission, which makes the final call on what medicines are cleared for market in European Union, referred the Leqembi case to an 'appeal committee.' These committees offer representatives from member countries a forum to further discuss proposed actions, such as the approval of a drug marketing application. A key regulatory committee sided against Leqembi's approval last summer, but reversed course after Eisai appealed that decision. — Jacob Bell Sanofi has made former GSK executive Chris Corsico its new head of development, according to an internal company communication obtained by BioPharma Dive. Corsico, whose new position is effective immediately, will report to Sanofi's global head of R&D Houman Ashrafian. At GSK, Corsico led development of the company's drug portfolio. He spent more than two decades at Boehringer Ingelheim previously. — Ned Pagliarulo Eye drug maker Opthea has scrapped plans to develop a treatment for a form of age-related macular degeneration, and warned investors it could run out of funding. In a Monday announcement, the company said it would terminate its Phase 3 trial of sozinibercept, which was tested as a combination with Lucentis. There 'remains material uncertainty as to Opthea's ability to continue as a going concern,' said the company, which had $100 million in cash and equivalents as of the end of March. — Gwendolyn Wu Novartis appointed Karen Hale as its new chief legal and compliance officer, the Swiss pharma said Sunday, replacing Klaus Moosmayer. Hale, who joined Novartis in 2021 from AbbVie to become its chief legal officer, will now also oversee the company's ethics and risk compliance policies. 'Strengthening enterprise-wide risk alignment and ensuring our commitment to ethics, compliance, and integrity remains a guiding force in everything we do,' Hale wrote in a LinkedIn post. — Gwendolyn Wu After years of regulatory back-and-forth, the European Commission will not renew the marketing authorization of PTC Therapeutics' drug Translarna to treat Duchenne muscular dystrophy. Effectively, Translarna is no longer approved in Europe, although individual countries can use certain pathways to allow continued use. Translarna was initially authorized in Europe in 2014, but in 2022 failed a confirmatory testing. European regulators have repeatedly recommended against the drug's continued availability, but those decisions went through several appeals. PTC is still working to win approval of Translarna in the U.S., where it has been rejected multiple times, too. — Ned Pagliarulo
